IL150756A0 - Novel use of hiv proteins - Google Patents

Novel use of hiv proteins

Info

Publication number
IL150756A0
IL150756A0 IL15075601A IL15075601A IL150756A0 IL 150756 A0 IL150756 A0 IL 150756A0 IL 15075601 A IL15075601 A IL 15075601A IL 15075601 A IL15075601 A IL 15075601A IL 150756 A0 IL150756 A0 IL 150756A0
Authority
IL
Israel
Prior art keywords
novel use
hiv proteins
hiv
proteins
novel
Prior art date
Application number
IL15075601A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002200A external-priority patent/GB0002200D0/en
Priority claimed from GB0009336A external-priority patent/GB0009336D0/en
Priority claimed from GB0013806A external-priority patent/GB0013806D0/en
Priority claimed from PCT/EP2000/005998 external-priority patent/WO2001000232A2/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of IL150756A0 publication Critical patent/IL150756A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15075601A 2000-01-31 2001-01-29 Novel use of hiv proteins IL150756A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0002200A GB0002200D0 (en) 2000-01-31 2000-01-31 Novel use
GB0009336A GB0009336D0 (en) 2000-04-14 2000-04-14 Novel use
GB0013806A GB0013806D0 (en) 2000-06-06 2000-06-06 Novel use
PCT/EP2000/005998 WO2001000232A2 (en) 1999-06-29 2000-06-28 Use of cpg as an adjuvant for hiv vaccine
PCT/EP2001/000944 WO2001054719A2 (en) 2000-01-31 2001-01-29 Vaccine for the prophylactic or therapeutic immunization against hiv

Publications (1)

Publication Number Publication Date
IL150756A0 true IL150756A0 (en) 2003-02-12

Family

ID=27255504

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15075601A IL150756A0 (en) 2000-01-31 2001-01-29 Novel use of hiv proteins

Country Status (23)

Country Link
US (3) US20030158134A1 (no)
EP (1) EP1251870A2 (no)
JP (1) JP2003529559A (no)
KR (2) KR20070073987A (no)
CN (1) CN1326873C (no)
AP (1) AP2002002592A0 (no)
AU (1) AU783005B2 (no)
BG (1) BG106964A (no)
BR (1) BR0107972A (no)
CA (1) CA2398611A1 (no)
CZ (1) CZ20022643A3 (no)
DZ (1) DZ3286A1 (no)
EA (1) EA200200724A1 (no)
HK (1) HK1051317A1 (no)
HU (1) HUP0204250A3 (no)
IL (1) IL150756A0 (no)
MX (1) MXPA02007413A (no)
NO (1) NO20023616L (no)
NZ (1) NZ520327A (no)
OA (1) OA12168A (no)
PL (1) PL211762B1 (no)
SK (1) SK11122002A3 (no)
WO (1) WO2001054719A2 (no)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
IT1297090B1 (it) * 1997-12-01 1999-08-03 Barbara Ensoli Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le
IL139813A0 (en) 1998-05-22 2002-02-10 Loeb Health Res Inst At The Ot Methods and products for inducing mucosal immunity
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
BR0108210A (pt) 2000-02-04 2002-10-22 Univ Duke Vacina contra o vìrus da imunodeficiência humana
WO2005090392A1 (en) * 2004-03-16 2005-09-29 Inist Inc. Tat-based tolerogen compositions and methods of making and using same
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
GB0118367D0 (en) * 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
EP1944043A1 (en) 2001-11-21 2008-07-16 The Trustees of the University of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
NZ550416A (en) 2001-11-21 2008-06-30 Univ Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
GB0206359D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US20050266024A1 (en) * 2002-03-19 2005-12-01 Powdermed Limited Adjuvant
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
NZ536499A (en) 2002-05-16 2008-04-30 Bavarian Nordic As Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
US7378234B2 (en) 2002-09-13 2008-05-27 Intercell Ag Method for isolating hepatitis C virus peptides
NZ540098A (en) 2002-10-29 2008-09-26 Coley Pharmaceutical Group Ltd Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
GB0225786D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
JP2006521321A (ja) * 2003-03-24 2006-09-21 インターツェル・アクチェンゲゼルシャフト 免疫応答を促進するためのミョウバンおよびＴｈ１免疫応答誘起アジュバントの使用
DE602004029657D1 (de) 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
US7943139B2 (en) 2004-01-09 2011-05-17 Morehouse School Of Medicine Methods of generating a humoral immune response against human immunodeficiency virus (HIV) comprising administering Nef apoptotic motif-containing polypeptide-conjugates
GB0405480D0 (en) * 2004-03-11 2004-04-21 Istituto Superiore Di Sanito Novel tat complexes,and vaccines comprising them
US7927580B2 (en) * 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
FR2868318B1 (fr) * 2004-04-01 2012-11-16 Commissariat Energie Atomique Antigene tat stabilise et ses applications pour la vaccination anti-vih
NZ561823A (en) 2005-03-23 2010-04-30 Glaxosmithkline Biolog Sa Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
EP2043682B1 (en) 2006-07-17 2014-04-02 GlaxoSmithKline Biologicals S.A. Influenza vaccine
US8926993B2 (en) * 2006-07-17 2015-01-06 Aduro Biotech Methods and compositions using Listeria for enhancing immunogenicity by prime boost
AU2007322016A1 (en) * 2006-11-17 2008-05-29 Duke University Multicomponent vaccine
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
SI2137210T1 (sl) * 2007-03-02 2017-01-31 Glaxosmithkline Biologicals S.A. Nov postopek in sestavki
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
MX2010005860A (es) 2007-11-28 2010-06-22 Univ Pennsylvania Adenovirus simianos de la subfamilia c sadv-40, sadv-31 y sadv-34 y usos de los mismos.
CN101883858B (zh) 2007-11-28 2015-07-22 宾夕法尼亚大学托管会 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用
CN102016011B (zh) 2008-03-04 2013-12-11 宾夕法尼亚大学托管会 猿猴腺病毒sadv-36、-42.1、-42.2和-44及其应用
US8940290B2 (en) 2008-10-31 2015-01-27 The Trustees Of The University Of Pennsylvania Simian adenoviruses SAdV-43, -45, -46, -47, -48, -49, and -50 and uses thereof
NZ595060A (en) 2009-03-23 2013-05-31 Pin Pharma Inc Treatment of cancer with immunostimulatory hiv tat derivative polypeptides
EP2435559A1 (en) 2009-05-29 2012-04-04 The Trustees Of The University Of Pennsylvania Simian adenovirus 41 and uses thereof
AU2011332025B2 (en) 2010-11-23 2015-06-25 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
AU2013262626B2 (en) 2012-05-18 2018-11-29 The Trustees Of The University Of Pennsylvania Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof
AU2014329393B2 (en) 2013-10-04 2020-04-30 Pin Pharma, Inc. Immunostimulatory HIV Tat derivative polypeptides for use in cancer treatment
CN106470736B (zh) 2014-05-13 2021-05-28 宾夕法尼亚州大学信托人 包括表达双抗体构建体的aav的组合物及其用途
CN104001155B (zh) * 2014-06-12 2016-04-13 中山大学 一种Tat蛋白及其制备方法和应用
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3565535A4 (en) 2017-01-05 2020-12-30 Fred Hutchinson Cancer Research Center SYSTEMS AND METHODS FOR IMPROVING THE EFFECTIVENESS OF A VACCINE
AU2021229710A1 (en) * 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
WO2022232289A1 (en) 2021-04-27 2022-11-03 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
JP3755890B2 (ja) * 1992-06-25 2006-03-15 スミスクライン・ビーチャム・バイオロジカルス（ソシエテ・アノニム） アジュバント含有ワクチン組成物
CA2215483C (fr) * 1995-03-08 2012-01-03 Jean-Francois Zagury Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
GB9720585D0 (en) * 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
FR2773156B1 (fr) * 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Also Published As

Publication number Publication date
PL357210A1 (en) 2004-07-26
US20030158134A1 (en) 2003-08-21
AU783005B2 (en) 2005-09-15
HUP0204250A3 (en) 2005-06-28
US20090104229A1 (en) 2009-04-23
CN1326873C (zh) 2007-07-18
US20050266025A1 (en) 2005-12-01
WO2001054719A3 (en) 2001-12-20
MXPA02007413A (es) 2004-07-30
NO20023616L (no) 2002-09-17
HK1051317A1 (zh) 2003-08-01
EA200200724A1 (ru) 2003-02-27
NO20023616D0 (no) 2002-07-30
BG106964A (bg) 2004-01-30
KR20020073569A (ko) 2002-09-27
HUP0204250A1 (hu) 2003-03-28
JP2003529559A (ja) 2003-10-07
OA12168A (en) 2006-05-08
NZ520327A (en) 2004-06-25
SK11122002A3 (sk) 2003-01-09
CZ20022643A3 (cs) 2003-02-12
EP1251870A2 (en) 2002-10-30
CN1419456A (zh) 2003-05-21
CA2398611A1 (en) 2001-08-02
PL211762B1 (pl) 2012-06-29
AP2002002592A0 (en) 2002-09-30
AU5791001A (en) 2001-08-07
DZ3286A1 (fr) 2001-08-02
WO2001054719A2 (en) 2001-08-02
BR0107972A (pt) 2002-11-05
KR100808348B1 (ko) 2008-02-27
KR20070073987A (ko) 2007-07-10

Similar Documents

Publication Publication Date Title
IL150756A0 (en) Novel use of hiv proteins
SG100740A1 (en) Disposable pants of trunks-type
GB0003079D0 (en) Novel protein
AU2000275763A1 (en) Expression of functional eukaryotic proteins
IL151523A0 (en) Use of avocado-soybean unsaponifiable preparations
AU5032501A (en) Use of cationic protein hydrolysates
GB0023289D0 (en) Determination of displacement
AU2001277750A1 (en) Use of polypeptide
EP1179592A4 (en) NECTIN-3 PROTEINS
GB0001700D0 (en) Novel protein
GB0024283D0 (en) Novel proteins
GB0018125D0 (en) Novel proteins
GB0027449D0 (en) Novel proteins
GB0018126D0 (en) Novel proteins
GB0028971D0 (en) Novel proteins
AU2001277614A1 (en) Novel proteins
AU2001267093A1 (en) Novel use of peptide
GB0010444D0 (en) Novel protein
GB0013637D0 (en) Novel protein
GB0026004D0 (en) Novel protein
GB0026619D0 (en) Novel protein
GB0031276D0 (en) Novel protein
GB0029547D0 (en) Novel protein
GB0025447D0 (en) Novel protein
GB0124025D0 (en) Novel protein